Chugai Pharmaceutical Co (CHGCF) Stock Statistics & Valuation Metrics
Total Valuation
Chugai Pharmaceutical Co has a market cap or net worth of $71.11B. The enterprise value is $9.39T.
- Market Cap
- $71.11B
- Enterprise Value
- $9.39T
Share Statistics
Chugai Pharmaceutical Co has 1,679,057,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,679,057,600
- Owned by Insiders
- ―
- Owned by Institutions
- 10.70%
Financial Efficiency
Chugai Pharmaceutical Co’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 20.83%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.18
- Return on Invested Capital (ROIC)
- 20.83%
- Return on Capital Employed (ROCE)
- 0.29
- Revenue Per Employee
- 246.46M
- Profits Per Employee
- 85.03M
- Employee Count
- 5,104
- Asset Turnover
- 0.51
- Inventory Turnover
- 1.31
Valuation Ratios
The current PE Ratio of Chugai Pharmaceutical Co is 22.36. Chugai Pharmaceutical Co’s PEG ratio is 0.83.
- PE Ratio
- 22.36
- PS Ratio
- 7.96
- PB Ratio
- 5.39
- Price to FCF
- 31.00
- Price to Operating Cash Flow
- 25.67
- PEG Ratio
- 0.83
Income Statement
In the last 12 months, Chugai Pharmaceutical Co had revenue of 1.26T and earned 434.01B in profits. Earnings per share was 263.73.
- Revenue
- 1.26T
- Gross Profit
- 894.25B
- Operating Income
- 590.19B
- Pretax Income
- 597.81B
- Net Income
- 434.01B
- EBITDA
- 631.37B
- Earnings Per Share (EPS)
- 263.73
Cash Flow
In the last 12 months, operating cash flow was 438.72B and capital expenditures -75.47B, giving a free cash flow of 363.25B billion.
- Operating Cash Flow
- 438.72B
- Free Cash Flow
- 363.25B
- Free Cash Flow per Share
- 220.74
Dividends & Yields
Chugai Pharmaceutical Co pays an annual dividend of $0.43, resulting in a dividend yield of 3.07%
- Dividend Per Share
- $0.43
- Dividend Yield
- 3.07%
- Payout Ratio
- 22.67%
- Free Cash Flow Yield
- 3.23%
- Earnings Yield
- 4.47%
Stock Price Statistics
- Beta
- -0.20
- 52-Week Price Change
- -2.66%
- 50-Day Moving Average
- 41.29
- 200-Day Moving Average
- 48.60
- Relative Strength Index (RSI)
- 55.47
- Average Volume (3m)
- 10.64K
Important Dates
Chugai Pharmaceutical Co upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Feb 04, 2027
- Ex-Dividend Date
- Dec 31, 2026
Financial Position
Chugai Pharmaceutical Co as a current ratio of 4.23, with Debt / Equity ratio of 0.00%
- Current Ratio
- 4.23
- Quick Ratio
- 3.56
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.68
- Interest Coverage Ratio
- 575.24
Taxes
In the past 12 months, Chugai Pharmaceutical Co has paid 163.79B in taxes.
- Income Tax
- 163.79B
- Effective Tax Rate
- 0.27
Enterprise Valuation
Chugai Pharmaceutical Co EV to EBITDA ratio is 15.44, with an EV/FCF ratio of 29.99.
- EV to Sales
- 7.70
- EV to EBITDA
- 15.44
- EV to Free Cash Flow
- 29.99
- EV to Operating Cash Flow
- 24.83
Balance Sheet
Chugai Pharmaceutical Co has $869.00B in cash and marketable securities with $16.14B in debt, giving a net cash position of $852.85B billion.
- Cash & Marketable Securities
- $869.00B
- Total Debt
- $16.14B
- Net Cash
- $852.85B
- Net Cash Per Share
- $507.93
- Tangible Book Value Per Share
- $1,233.36
Margins
Gross margin is 71.50%, with operating margin of 46.53%, and net profit margin of 35.61%.
- Gross Margin
- 71.50%
- Operating Margin
- 46.53%
- Pretax Margin
- 49.76%
- Net Profit Margin
- 35.61%
- EBITDA Margin
- 49.90%
- EBIT Margin
- 48.44%
Analyst Forecast
The average price target for Chugai Pharmaceutical Co is $51.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $51.20
- Price Target Upside
- 16.90% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- 10.35%
- EPS Growth Forecast
- 20.09%
